1. Home
  2. INSM vs ES Comparison

INSM vs ES Comparison

Compare INSM & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ES
  • Stock Information
  • Founded
  • INSM 1988
  • ES 1927
  • Country
  • INSM United States
  • ES United States
  • Employees
  • INSM N/A
  • ES N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ES Electric Utilities: Central
  • Sector
  • INSM Health Care
  • ES Utilities
  • Exchange
  • INSM Nasdaq
  • ES Nasdaq
  • Market Cap
  • INSM 29.0B
  • ES 27.7B
  • IPO Year
  • INSM 2000
  • ES N/A
  • Fundamental
  • Price
  • INSM $182.69
  • ES $73.87
  • Analyst Decision
  • INSM Strong Buy
  • ES Hold
  • Analyst Count
  • INSM 19
  • ES 11
  • Target Price
  • INSM $171.12
  • ES $70.10
  • AVG Volume (30 Days)
  • INSM 2.1M
  • ES 2.4M
  • Earning Date
  • INSM 10-30-2025
  • ES 11-04-2025
  • Dividend Yield
  • INSM N/A
  • ES 4.08%
  • EPS Growth
  • INSM N/A
  • ES N/A
  • EPS
  • INSM N/A
  • ES 2.35
  • Revenue
  • INSM $447,022,000.00
  • ES $12,991,135,000.00
  • Revenue This Year
  • INSM $40.09
  • ES $10.24
  • Revenue Next Year
  • INSM $129.64
  • ES $4.17
  • P/E Ratio
  • INSM N/A
  • ES $31.45
  • Revenue Growth
  • INSM 30.34
  • ES 14.44
  • 52 Week Low
  • INSM $60.40
  • ES $52.28
  • 52 Week High
  • INSM $197.08
  • ES $75.25
  • Technical
  • Relative Strength Index (RSI)
  • INSM 67.29
  • ES 61.04
  • Support Level
  • INSM $178.76
  • ES $72.31
  • Resistance Level
  • INSM $197.08
  • ES $75.25
  • Average True Range (ATR)
  • INSM 7.01
  • ES 1.33
  • MACD
  • INSM 1.60
  • ES -0.18
  • Stochastic Oscillator
  • INSM 65.96
  • ES 65.97

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About ES Eversource Energy (D/B/A)

Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.

Share on Social Networks: